Chemoprophylaxis for HIV prevention: new opportunities and new questions. - Wikidata - wikimedia - TriplyDB

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

http://www.wikidata.org/entity/Q34786284

about

Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS Passing the baton: Community-based ethnography to design a randomized clinical trial on the effectiveness of oral pre-exposure prophylaxis for HIV prevention among Black men who have sex with men.Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand Experience in international clinical research: the HIV Prevention Trials Network.Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide

P2860

Q28260539-8A52D325-EF29-4DA9-855B-6A1FAFFB4567 Q34498357-6DED060A-C046-4849-AAEC-34B5D01921D1 Q35014785-496CB388-CCEE-49DE-B204-792FF6CB8755 Q35762863-CFDBE27F-5681-4E2E-B367-2E22FAA6C06E Q35941336-CD29972D-1016-45A0-BCAE-C5EFE779C4DC

P2860

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

http://www.wikidata.org/entity/Q34786284

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

@ast

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

@en

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

@nl

type

label

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

@ast

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

@en

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

@nl

prefLabel

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

@ast

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

@en

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

@nl

P1433

Q34786284-8F193D97-2241-48DE-8CC2-DC9323C6B20F

P1476

Q34786284-628F69D7-2524-4B26-AEE6-14A8D2E3FE6E

P2093

Q34786284-A1677BA3-3BFB-4134-88AA-1075595BBF6B

P2860

Q34786284-00169ADD-213F-40AB-B610-B4971E07D944

Q34786284-164BF22A-0386-474B-ABC1-B9526DDA6090

Q34786284-1D4BF8B8-A206-47BC-8109-FD4E6469D871

Q34786284-27102F81-00F2-4F4C-8DBA-7FA08B170483

Q34786284-2CE5FE40-A8CD-4B90-A7C3-45194FE2C659

Q34786284-37990E3E-24F4-44B2-A90A-62167280ECE5

Q34786284-38268F44-0A26-4A85-8FDE-B0A171FDBB9B

Q34786284-405FF56F-D3ED-49CA-80C2-091FE44502CE

Q34786284-4362C24A-7C4E-4891-8C81-99529468D571

Q34786284-4509EA15-2B7C-4CCC-87AA-3EEE85357F74

P304

Q34786284-99144718-5FA7-4E28-95B8-27BA0CBFE860

P31

Q34786284-0DC28E52-87B6-495B-9AA7-94241FBEB4D5

P356

Q34786284-60C967DF-EB84-4C74-BA71-317633D4223A

P407

Q34786284-AAE703AF-0469-48BA-AA34-A6B67867257C

P478

Q34786284-47893602-1F76-4140-9287-C96F08D87BA9

P50

Q34786284-B788108A-D851-40F7-8A1A-21F8FDD53801

P577

Q34786284-4CDB0AE5-22F6-4F60-AB42-D8B0510A1E60

P698

Q34786284-546AB912-A504-4259-B3AE-F81CE1294A62

P921

Q34786284-8757577C-5F16-4C87-85D1-92DD05F9CCD8

P932

Q34786284-176F82C0-D7BA-4037-B605-5589FEB12C85

P356

QAI.0B013E3181FBCB4C

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Chemoprophylaxis for HIV prevention: new opportunities and new questions.

@en

P2093

Kartik K Venkatesh

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial

HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model

Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice.

Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings

Antiretroviral therapy for prevention of HIV infection: new clues from an animal model.

Highly active antiretroviral treatment for the prevention of HIV transmission.

P304

S122-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E3181FBCB4C

http://www.w3.org/2001/XMLSchema#string

P407

P478

55 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21406981

http://www.w3.org/2001/XMLSchema#string

P921

prevention of HIV/AIDS

P932

3075435

http://www.w3.org/2001/XMLSchema#string